REXIGO 120 MG

Relugolix occupies a defined place in systemic cancer care, but that place depends on the malignancy and treatment setting. Hormone-pathway suppression is the central therapeutic principle, with treatment selection shaped by the prostate cancer disease state or other hormone-sensitive context described in the indication. Directly antagonizes pituitary GnRH receptors, suppressing LH/FSH and testosterone. Unlike injectable GnRH agonist entries, the supplied record identifies this medicine as an oral GnRH receptor antagonist for androgen deprivation in advanced prostate cancer. Its classification is Hormonal / Endocrine Therapy; ADT, and the database links it with Prostate Cancer. The listed indications are Advanced prostate cancer requiring androgen deprivation. Treatment examples include Relugolix monotherapy for ADT; relugolix + androgen-pathway agents. These regimens illustrate the practical context in which the medicine is used and, where applicable, the partners that complement its pharmacologic effect. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. Particular attention should be given to any biomarker, receptor expression, mutation, treatment-line, or prior-therapy requirement explicitly included in the indication field. Such details can determine whether a cancer diagnosis actually matches the documented use. The drug's class should be considered alongside its individual mechanism, since agents within the same broad category may differ in target specificity and clinical positioning.